|
Post by madog365 on Dec 5, 2016 15:12:28 GMT -5
I confirmed with IR that the technical objectives necessary for first milestone payment were in fact completed in November (by MNKD), just as Matt said on the Q3 call. The holdup in milestone payment is on Receptor's end where Mannkind is waiting for their approval/acceptance. They did say that a PR would likely happen once this payment is made. Also they are anticipating moving forward in early next year with the next stage of the partnership which is product development.
The ball is in RLS court. When will the approval happen? No idea.
|
|
|
Post by uvula on Dec 5, 2016 15:28:50 GMT -5
I confirmed with IR that the technical objectives necessary for first milestone payment were in fact completed in November (by MNKD), just as Matt said on the Q3 call. The holdup in milestone payment is on Receptor's end where Mannkind is waiting for their approval/acceptance. They did say that a PR would likely happen once this payment is made. Also they are anticipating moving forward in early next year with the next stage of the partnership which is product development. The ball is in RLS court. When will the approval happen? No idea. I seldom make personal attacks on the internet, but either you are lying or someone in IR is breaking the law if they really told you that.
|
|
|
Post by madog365 on Dec 5, 2016 15:34:20 GMT -5
I confirmed with IR that the technical objectives necessary for first milestone payment were in fact completed in November (by MNKD), just as Matt said on the Q3 call. The holdup in milestone payment is on Receptor's end where Mannkind is waiting for their approval/acceptance. They did say that a PR would likely happen once this payment is made. Also they are anticipating moving forward in early next year with the next stage of the partnership which is product development. The ball is in RLS court. When will the approval happen? No idea. I seldom make personal attacks on the internet, but either you are lying or someone in IR is breaking the law if they really told you that. Not sure what you mean? They disclosed this in their Q3 earnings call and then confirmed it via email. What piece would be considered new information?
|
|
|
Post by uvula on Dec 5, 2016 15:36:38 GMT -5
I seldom make personal attacks on the internet, but either you are lying or someone in IR is breaking the law if they really told you that. Not sure what you mean? They disclosed this in their Q3 earnings call and then confirmed it via email. What piece would be considered new information? My sincere apology if this is correct. I thought Matt said something like they expect to meet the milestone soon, which is very different than actually meeting the milestone.
|
|
|
Post by peppy on Dec 5, 2016 15:43:48 GMT -5
the Rohrabacher-Farr Amendment, which is intended to prevent the DOJ and DEA from arresting or prosecuting patients, caregivers, and businesses that are acting in compliance with state medical marijuana laws; the spending plan also renews the Harris Amendment, which prevents the District of Columbia from regulating marijuana for adult use www.mpp.org/news/press/ban-on-justice-department-interference-in-state-medical-marijuana-laws-to-continue/Note date: Dec 16, 2015 first approved in the House of Representatives in May 2014 and included in the Consolidated and Further Continuing Appropriations Act of 2015 signed by President Obama last December. “Marijuana is now legal for adults in the District of Columbia, and it needs to be treated like a legal product,”
|
|
|
Post by mnkdfann on Dec 5, 2016 15:50:07 GMT -5
Not sure what you mean? They disclosed this in their Q3 earnings call and then confirmed it via email. What piece would be considered new information? My sincere apology if this is correct. I thought Matt said something like they expect to meet the milestone soon, which is very different than actually meeting the milestone. According to the transcript, this is what was said about RLS: seekingalpha.com/article/4021887-mannkinds-mnkd-ceo-matthew-pfeffer-q3-2016-results-earnings-call-transcript?part=single"We also continue to make progress in our receptor life sciences collaboration and we’ll achieve certain predetermined tactical objectives later this month." It doesn't explicitly say those predetermined tactical objectives were tied to a milestone payment, but I guess it is not a huge inference to make.
|
|
|
Post by nylefty on Dec 5, 2016 16:23:27 GMT -5
the Rohrabacher-Farr Amendment, which is intended to prevent the DOJ and DEA from arresting or prosecuting patients, caregivers, and businesses that are acting in compliance with state medical marijuana laws; the spending plan also renews the Harris Amendment, which prevents the District of Columbia from regulating marijuana for adult use www.mpp.org/news/press/ban-on-justice-department-interference-in-state-medical-marijuana-laws-to-continue/Note date: Dec 16, 2015 first approved in the House of Representatives in May 2014 and included in the Consolidated and Further Continuing Appropriations Act of 2015 signed by President Obama last December. “This amendment has teeth, but only as long as it keeps getting renewed,” Capecchi said. “It’s time for Congress to adopt a more permanent solution. The CARERS Act is one option, but Sen. Grassley is not allowing it to get a committee hearing. Unfortunately, some members are still clinging to antiquated prohibition policies.”
|
|
|
Post by sportsrancho on Dec 5, 2016 16:26:39 GMT -5
Madog365.....Makes sense to me. Can't wait for ( product development ) this is going to be fun!
|
|
|
Post by mango on Dec 5, 2016 18:14:42 GMT -5
I wonder if any of this has to do with MannKind's efforts with RLS? 1) Raymond Urbanski Name: MANNKIND CORPORATION, RAYMOND URBANSKI DBA: MANNKIND CORPORATION Address: 1 CASPER ST LAB 208 DANBURY, CT 06810-6903 Credential: CSL.0001138 License Type: CONTROLLED SUBSTANCE LABORATORY Effective Date: 02/22/2016 Expiration Date: 01/31/2017 Status: ACTIVE Name: MANNKIND CORP DBA: Address: 1 CASPER ST DANBURY, CT 06810-6903 Credential: CSM.0000766 License Type: MANUFACTURER OF DRUGS, COSMETICS & MEDICAL DEVICES Effective Date: 07/01/2016 Expiration Date: 06/30/2017 Status: ACTIVE www.elicense.ct.gov/Lookup/LicenseLookup.aspx2) Hakan Edstrom: Director of MannKind Limited located in the UK from July 6, 2005 — Janruary 26, 2016 • MannKind Limited — Application filed to strike the company off the register September 27, 2015 (David Thomson also is on the paperwork) — MannKind Limited was dissolved on Janruary 26, 2016 beta.companieshouse.gov.uk/officers/A8qynK9ax8vG5nEgKrtwIeaqyVM/appointments beta.companieshouse.gov.uk/company/05471047 Interestingly enough, MannKind LLC showed back up on the SEC filing concerning the debt forgiveness with Sanofi/Aventisub LLC I wonder when Hakan Edstrom will come back into the MannKind story?
|
|
|
Post by slugworth008 on Dec 5, 2016 18:48:48 GMT -5
I wonder if any of this has to do with MannKind's efforts with RLS? 1) Raymond Urbanski Name: MANNKIND CORPORATION, RAYMOND URBANSKI DBA: MANNKIND CORPORATION Address: 1 CASPER ST LAB 208 DANBURY, CT 06810-6903 Credential: CSL.0001138 License Type: CONTROLLED SUBSTANCE LABORATORY Effective Date: 02/22/2016 Expiration Date: 01/31/2017 Status: ACTIVE Name: MANNKIND CORP DBA: Address: 1 CASPER ST DANBURY, CT 06810-6903 Credential: CSM.0000766 License Type: MANUFACTURER OF DRUGS, COSMETICS & MEDICAL DEVICES Effective Date: 07/01/2016 Expiration Date: 06/30/2017 Status: ACTIVE www.elicense.ct.gov/Lookup/LicenseLookup.aspx2) Hakan Edstrom: Director of MannKind Limited located in the UK from July 6, 2005 — Janruary 26, 2016 • MannKind Limited — Application filed to strike the company off the register September 27, 2015 (David Thomson also is on the paperwork) — MannKind Limited was dissolved on Janruary 26, 2016 beta.companieshouse.gov.uk/officers/A8qynK9ax8vG5nEgKrtwIeaqyVM/appointments beta.companieshouse.gov.uk/company/05471047 Interestingly enough, MannKind LLC showed back up on the SEC filing concerning the debt forgiveness with Sanofi/Aventisub LLC I wonder when Hakan Edstrom will come back into the MannKind story? Who knows - But I do know this....I'm not waiting for an RLS cannabis product. MNKD has sent me to the local dispensary already. Sorry but I just had to have a little fun with this one.
|
|
|
Post by mango on Dec 5, 2016 19:27:06 GMT -5
I wonder if any of this has to do with MannKind's efforts with RLS? 1) Raymond Urbanski Name: MANNKIND CORPORATION, RAYMOND URBANSKI DBA: MANNKIND CORPORATION Address: 1 CASPER ST LAB 208 DANBURY, CT 06810-6903 Credential: CSL.0001138 License Type: CONTROLLED SUBSTANCE LABORATORY Effective Date: 02/22/2016 Expiration Date: 01/31/2017 Status: ACTIVE Name: MANNKIND CORP DBA: Address: 1 CASPER ST DANBURY, CT 06810-6903 Credential: CSM.0000766 License Type: MANUFACTURER OF DRUGS, COSMETICS & MEDICAL DEVICES Effective Date: 07/01/2016 Expiration Date: 06/30/2017 Status: ACTIVE www.elicense.ct.gov/Lookup/LicenseLookup.aspx2) Hakan Edstrom: Director of MannKind Limited located in the UK from July 6, 2005 — Janruary 26, 2016 • MannKind Limited — Application filed to strike the company off the register September 27, 2015 (David Thomson also is on the paperwork) — MannKind Limited was dissolved on Janruary 26, 2016 beta.companieshouse.gov.uk/officers/A8qynK9ax8vG5nEgKrtwIeaqyVM/appointments beta.companieshouse.gov.uk/company/05471047 Interestingly enough, MannKind LLC showed back up on the SEC filing concerning the debt forgiveness with Sanofi/Aventisub LLC I wonder when Hakan Edstrom will come back into the MannKind story? Who knows - But I do know this....I'm not waiting for an RLS cannabis product. MNKD has sent me to the local dispensary already. Sorry but I just had to have a little fun with this one. I personally do not think MannKind is or will be in the recreational cannabis market. I think they will be involved with big things though, specifically, cannabinoid compounds. An overwhelming amount of studies show cannabinoids inhibit proliferation and induce cancer cell death. Cannabinoid receptors are present in cancer cells, so developing cannabinoid compounds and different delivery systems will be something of a continuous need. Check out Manuel Guzman and his work, he is doing really amazing work. His research has shown significant results, and one study involved injecting THC directly into cancerous tumors of mice and this resulted in 30% of the mice with cancerous tumors completely cancer free with their tumor 100% diminished and the remaining mice showed significant tumor size reduction. Smoking cannabis alone cannot achieve this, and that is why isolating phyocannabinoid compounds to target specific receptor sites is important.
|
|
|
Post by letitride on Dec 5, 2016 20:07:41 GMT -5
I know that smoking pot isn't suppose to cure cancer but I believe second hand pot smoke may cause remission.
|
|
|
Post by 2011mnkdguy on Dec 6, 2016 9:42:30 GMT -5
|
|
|
Post by peppy on Dec 6, 2016 10:00:22 GMT -5
whether England or the USA, NIDA, National institute Drug Abuse
Study submitted with end point of," Does Marijuana have a medicinal benefit?"
"The first two requests never could be granted because NIDA is the only legal source for research marijuana in the country.
NIDA has a congressional mandate to study substances of abuse AS SUBSTANCES OF ABUSE.
We are the national institute ON DRUG ABUSE NOT for Drug abuse. So we can not give you marijuana to see if it has a medicinal benefit.
23 minutes into the video. www.youtube.com/watch?v=2ukz7YfStkI
My words, interesting information as cannabis can only be studied as an abused drug. Also interesting, GWPH, in England. www.screencast.com/t/9VIcUj1Ek
|
|
|
Post by audiomr on Dec 6, 2016 12:49:10 GMT -5
I wonder what drove the shift in strategy Madog (Mattis). :-) Driven by need for speed and limited resources. This is why EpiHale is not at the front of the queue. Sorry. Meant to say "this is why EpiHale is at the front of the queue. Is there a way to edit one's own posts on this board?
|
|